{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T18:40:15Z","timestamp":1772563215569,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2023YFS0417"],"award-info":[{"award-number":["2023YFS0417"]}]},{"name":"Research Project of China Baoyuan Investment Co., Ltd","award":["CBYI202102"],"award-info":[{"award-number":["CBYI202102"]}]},{"name":"Medical Youth Innovation Project of Sichuan Province","award":["Q22060"],"award-info":[{"award-number":["Q22060"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant pleural effusion (MPE) is frequently observed in patients with advanced lung adenocarcinoma (LUAD). Pleural fluid cytology is a less invasive procedure compared to pleural biopsy. Therefore, it is crucial to identify novel effective biomarkers for LUAD-associated pleural fluid cytology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The RNA sequencing (RNA-Seq) and clinical data of LUAD cases were downloaded from TCGA and OncoSG databases. Differential gene expression analysis, survival analysis and immune cell infiltration analysis were performed on the LUAD datasets. The expression levels of FAM83A, TFF-1, and NapsinA in 94 paired LUAD and adjacent normal tissues, and in the pleural effusion specimens of 40 LUAD and 21 non-neoplastic patients were evaluated by immunohistochemistry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>FAM83A expression levels were significantly different between the LUAD and normal tissue datasets, and correlated with overall or disease-free survival, and histological grade of the tumors. Furthermore, the in-situ expression of FAM83A was higher in 89\/94 LUAD tissues compared to the paired normal tissues. FAM83A expression was significantly correlated with immune cell infiltration, and showed a positive association with macrophage infiltration. In addition, FAM83A staining was positive in 37 LUAD pleural effusion samples, and negative in 20 non-neoplastic pleural effusion samples. The expression pattern of FAM83A in the pleural effusion of LUAD patients was relatively consistent with that of TFF-1 and NapsinA, and even stronger in some specimens that were weakly positive or negative for TTF1\/NapsinA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>FAM83A is a promising immune-related biomarker in LUAD biopsy specimens and pleural fluid, and can distinguish between malignant and benign pleural effusion.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-024-01109-7","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T19:57:49Z","timestamp":1719259069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9231-212X","authenticated-orcid":false,"given":"Hangfeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuanghua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"1109_CR1","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1186\/s12885-019-6101-7","volume":"19","author":"Y Li","year":"2019","unstructured":"Li Y, Ge D, Gu J, et al. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies. BMC Cancer. 2019;19:886.","journal-title":"BMC Cancer"},{"key":"1109_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.chest.2016.11.010","volume":"151","author":"N Taghizadeh","year":"2017","unstructured":"Taghizadeh N, Fortin M, Tremblay A. US Hospitalizations for malignant pleural effusions: data from the 2012 National inpatient sample. Chest. 2017;151:845\u201354.","journal-title":"Chest"},{"key":"1109_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1378\/chest.08-2968","volume":"136","author":"WN William Jr","year":"2009","unstructured":"William WN Jr, Lin HY, Lee JJ, et al. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009;136:701\u20139.","journal-title":"Chest"},{"key":"1109_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12890-017-0526-z","volume":"17","author":"J Wang","year":"2017","unstructured":"Wang J, Liu J, Xie X, et al. The pleural fluid lactate dehydrogenase\/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions. BMC Pulm Med. 2017;17:168.","journal-title":"BMC Pulm Med"},{"key":"1109_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.clinbiochem.2010.05.016","volume":"43","author":"JS Hackbarth","year":"2010","unstructured":"Hackbarth JS, Murata K, Reilly WM, et al. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies. Clin Biochem. 2010;43:1051\u20135.","journal-title":"Clin Biochem"},{"key":"1109_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1378\/chest.126.6.1757","volume":"126","author":"JM Porcel","year":"2004","unstructured":"Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15\u20133, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757\u201363.","journal-title":"Chest"},{"key":"1109_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23091","volume":"34","author":"F Zhang","year":"2020","unstructured":"Zhang F, Wang J, Fu J, et al. Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion. J Clin Lab Anal. 2020;34: e23091.","journal-title":"J Clin Lab Anal"},{"key":"1109_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","volume":"82","author":"J Creaney","year":"2013","unstructured":"Creaney J, Dick IM, Segal A, et al. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82:491\u20138.","journal-title":"Lung Cancer"},{"key":"1109_CR9","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.currproblcancer.2018.10.001","volume":"43","author":"S Javath Hussain","year":"2019","unstructured":"Javath Hussain S, Selvaraj J, Mohanty Mohapatra M, et al. Clinical utility of pleural fluid YKL-40 as a marker of malignant pleural effusion. Curr Probl Cancer. 2019;43:354\u201362.","journal-title":"Curr Probl Cancer"},{"key":"1109_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22901","volume":"33","author":"T Tian","year":"2019","unstructured":"Tian T, Li J, Hu W, et al. Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion. J Clin Lab Anal. 2019;33: e22901.","journal-title":"J Clin Lab Anal"},{"key":"1109_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1186\/s12885-020-07327-w","volume":"20","author":"H Choi","year":"2020","unstructured":"Choi H, Ko Y, Lee CY. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study. BMC Cancer. 2020;20:825.","journal-title":"BMC Cancer"},{"key":"1109_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12885-020-06851-z","volume":"20","author":"Y Zou","year":"2020","unstructured":"Zou Y, Xu L, Tang Q, et al. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. BMC Cancer. 2020;20:344.","journal-title":"BMC Cancer"},{"key":"1109_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5858\/arpa.2011-0320-OA","volume":"136","author":"BM Turner","year":"2012","unstructured":"Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163\u201371.","journal-title":"Arch Pathol Lab Med"},{"key":"1109_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/resp.12543","volume":"20","author":"JM Porcel","year":"2015","unstructured":"Porcel JM, Palma R, Bielsa S, et al. TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. Respirology (Carlton, Vic). 2015;20:831\u20133.","journal-title":"Respirology (Carlton, Vic)"},{"key":"1109_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cncy.20135","volume":"119","author":"N Fatima","year":"2011","unstructured":"Fatima N, Cohen C, Lawson D, et al. TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol. 2011;119:127\u201333.","journal-title":"Cancer Cytopathol"},{"key":"1109_CR16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1541-7786.MCR-13-0289","volume":"12","author":"R Cipriano","year":"2014","unstructured":"Cipriano R, Miskimen KL, Bryson BL, et al. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res. 2014;12:1156\u201365.","journal-title":"Mol Cancer Res"},{"key":"1109_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao2341","author":"LJ Fulcher","year":"2018","unstructured":"Fulcher LJ, Bozatzi P, Tachie-Menson T, et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Sci Signal. 2018. https:\/\/doi.org\/10.1126\/scisignal.aao2341.","journal-title":"Sci Signal"},{"key":"1109_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1878-0261.12016","volume":"11","author":"AM Snijders","year":"2017","unstructured":"Snijders AM, Lee SY, Hang B, et al. FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach. Mol Oncol. 2017;11:167\u201379.","journal-title":"Mol Oncol"},{"key":"1109_CR19","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1172\/JCI64412","volume":"122","author":"S Grant","year":"2012","unstructured":"Grant S. FAM83A and FAM83B: candidate oncogenes and TKI resistance mediators. J Clin Invest. 2012;122:3048\u201351.","journal-title":"J Clin Invest"},{"key":"1109_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40364-022-00353-9","volume":"10","author":"N Marino","year":"2022","unstructured":"Marino N, German R, Podicheti R, et al. FAM83A is a potential biomarker for breast cancer initiation. Biomarker Res. 2022;10:8.","journal-title":"Biomarker Res"},{"key":"1109_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12957-022-02636-9","volume":"20","author":"Y Jin","year":"2022","unstructured":"Jin Y, Yu J, Jiang Y, et al. Comprehensive analysis of the expression, prognostic significance, and function of FAM83 family members in breast cancer. World J Surg Oncol. 2022;20:172.","journal-title":"World J Surg Oncol"},{"key":"1109_CR22","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1172\/JCI60498","volume":"122","author":"SY Lee","year":"2012","unstructured":"Lee SY, Meier R, Furuta S, et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest. 2012;122:3211\u201320.","journal-title":"J Clin Invest"},{"key":"1109_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176778","volume":"12","author":"CA Bartel","year":"2017","unstructured":"Bartel CA, Jackson MW. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss. PLoS ONE. 2017;12: e0176778.","journal-title":"PLoS ONE"},{"key":"1109_CR24","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.2147\/CMAR.S276316","volume":"12","author":"C Liu","year":"2020","unstructured":"Liu C, Jiang Y, Han B. miR-613 suppresses chemoresistance and stemness in triple-negative breast cancer by targeting FAM83A. Cancer Manag Res. 2020;12:12623\u201333.","journal-title":"Cancer Manag Res"},{"key":"1109_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/tox.23435","volume":"37","author":"J Zhao","year":"2022","unstructured":"Zhao J, Zhao F, Yang T, et al. FAM83A has a pro-tumor function in ovarian cancer by affecting the Akt\/Wnt\/\u03b2-catenin pathway. Environ Toxicol. 2022;37:695\u2013707.","journal-title":"Environ Toxicol"},{"key":"1109_CR26","doi-asserted-by":"publisher","first-page":"1093042","DOI":"10.3389\/fendo.2023.1093042","volume":"14","author":"W Zou","year":"2023","unstructured":"Zou W, Wang H, Wu D, et al. ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer. Front Endocrinol. 2023;14:1093042.","journal-title":"Front Endocrinol"},{"key":"1109_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.3","volume":"6","author":"S Chen","year":"2017","unstructured":"Chen S, Huang J, Liu Z, et al. FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogenesis. 2017;6: e300.","journal-title":"Oncogenesis"},{"key":"1109_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41392-022-01268-5","volume":"8","author":"C Zhou","year":"2023","unstructured":"Zhou C, Zhu X, Liu N, et al. B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with \u03b2-catenin. Signal Transduct Target Ther. 2023;8:66.","journal-title":"Signal Transduct Target Ther"},{"key":"1109_CR29","doi-asserted-by":"publisher","first-page":"13396","DOI":"10.1038\/s41598-019-49475-5","volume":"9","author":"N Parameswaran","year":"2019","unstructured":"Parameswaran N, Bartel CA, Hernandez-Sanchez W, et al. A FAM83A positive feed-back loop drives survival and tumorigenicity of pancreatic ductal adenocarcinomas. Sci Rep. 2019;9:13396.","journal-title":"Sci Rep"},{"key":"1109_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/ijo.2020.5078","volume":"57","author":"J Xu","year":"2020","unstructured":"Xu J, Lu W. FAM83A exerts tumorsuppressive roles in cervical cancer by regulating integrins. Int J Oncol. 2020;57:509\u201321.","journal-title":"Int J Oncol"},{"key":"1109_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.608441","volume":"7","author":"L Rong","year":"2020","unstructured":"Rong L, Li H, Li Z, et al. FAM83A as a potential biological marker is regulated by mir-206 to promote cervical cancer progression through PI3K\/AKT\/mTOR pathway. Front Med (Lausanne). 2020;7: 608441.","journal-title":"Front Med (Lausanne)"},{"key":"1109_CR32","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.7150\/jca.62563","volume":"12","author":"C Lan","year":"2021","unstructured":"Lan C, Liu CC, Nie XC, et al. FAM83A promotes the proliferative and invasive abilities of cervical cancer cells via epithelial-mesenchymal transition and the Wnt Signaling pathway. J Cancer. 2021;12:6320\u20139.","journal-title":"J Cancer"},{"key":"1109_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12967-021-03089-6","volume":"19","author":"H Ji","year":"2021","unstructured":"Ji H, Song H, Wang Z, et al. FAM83A promotes proliferation and metastasis via Wnt\/\u03b2-catenin signaling in head neck squamous cell carcinoma. J Transl Med. 2021;19:423.","journal-title":"J Transl Med"},{"key":"1109_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109780","volume":"123","author":"C Liu","year":"2020","unstructured":"Liu C, Peng X, Li Y, et al. Positive feedback loop of FAM83A\/PI3K\/AKT\/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma. Biomed Pharmacother. 2020;123: 109780.","journal-title":"Biomed Pharmacother"},{"key":"1109_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228833","author":"PJ Liu","year":"2020","unstructured":"Liu PJ, Chen YH, Tsai KW, et al. Involvement of MicroRNA-1-FAM83A axis dysfunction in the growth and motility of lung cancer cells. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21228833.","journal-title":"Int J Mol Sci"},{"key":"1109_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fonc.2020.00180","volume":"10","author":"YW Zheng","year":"2020","unstructured":"Zheng YW, Li ZH, Lei L, et al. FAM83A promotes lung cancer progression by regulating the Wnt and Hippo signaling pathways and indicates poor prognosis. Front Oncol. 2020;10:180.","journal-title":"Front Oncol"},{"key":"1109_CR37","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7150\/ijms.33992","volume":"17","author":"H Hu","year":"2020","unstructured":"Hu H, Wang F, Wang M, et al. FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K\/Akt\/mTOR pathways. Int J Med Sci. 2020;17:807\u201314.","journal-title":"Int J Med Sci"},{"key":"1109_CR38","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.18632\/aging.102163","volume":"11","author":"F Zhou","year":"2019","unstructured":"Zhou F, Geng J, Xu S, et al. FAM83A signaling induces epithelial-mesenchymal transition by the PI3K\/AKT\/Snail pathway in NSCLC. Aging (Albany NY). 2019;11:6069\u201388.","journal-title":"Aging (Albany NY)"},{"key":"1109_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050652","author":"S Richtmann","year":"2019","unstructured":"Richtmann S, Wilkens D, Warth A, et al. FAM83A and FAM83B as prognostic biomarkers and potential new therapeutic targets in NSCLC. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11050652.","journal-title":"Cancers (Basel)"},{"key":"1109_CR40","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1089\/dna.2019.4970","volume":"39","author":"J Yu","year":"2020","unstructured":"Yu J, Hou M, Pei T. FAM83A is a prognosis signature and potential oncogene of lung adenocarcinoma. DNA Cell Biol. 2020;39:890\u20139.","journal-title":"DNA Cell Biol"},{"key":"1109_CR41","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.12659\/MSM.910804","volume":"25","author":"JT Zhang","year":"2019","unstructured":"Zhang JT, Lin YC, Xiao BF, et al. Overexpression of family with sequence similarity 83, member A (FAM83A) predicts poor clinical outcomes in lung adenocarcinoma. Med Sci Monit. 2019;25:4264\u201372.","journal-title":"Med Sci Monit"},{"key":"1109_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/CBM-190520","volume":"26","author":"J Zhang","year":"2019","unstructured":"Zhang J, Sun G, Mei X. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma. Cancer Biomark. 2019;26:367\u201373.","journal-title":"Cancer Biomark"},{"key":"1109_CR43","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s10147-020-01696-9","volume":"25","author":"F Zhou","year":"2020","unstructured":"Zhou F, Wang X, Liu F, et al. FAM83A drives PD-L1 expression via ERK signaling and FAM83A\/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. Int J Clin Oncol. 2020;25:1612\u201323.","journal-title":"Int J Clin Oncol"},{"key":"1109_CR44","doi-asserted-by":"publisher","first-page":"8767333","DOI":"10.1155\/2022\/8767333","volume":"2022","author":"X Liu","year":"2022","unstructured":"Liu X, Fu M, Xia D, et al. Overexpression of FAM83A Is associated with poor prognosis of lung adenocarcinoma. J Oncol. 2022;2022:8767333.","journal-title":"J Oncol"},{"key":"1109_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.723172","volume":"12","author":"Z Huang","year":"2021","unstructured":"Huang Z, Li B, Guo Y, et al. Signatures of multi-omics reveal distinct tumor immune microenvironment contributing to immunotherapy in lung adenocarcinoma. Front Immunol. 2021;12: 723172.","journal-title":"Front Immunol"},{"key":"1109_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244\u201385.","journal-title":"J Thorac Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01109-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01109-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T20:33:16Z","timestamp":1719261196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01109-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01109-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the Ethics Committee of the Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained for experimentation with human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}